Bristol-Myers Squibb (BMY) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Bristol-Myers Squibb Revenue Highlights

Latest Revenue (Y)

$48.30B

Latest Revenue (Q)

$12.22B

Main Segment (Y)

Eliquis

Main Geography (Y)

UNITED STATES

Bristol-Myers Squibb Revenue by Period

Bristol-Myers Squibb Revenue by Year

Date	Revenue	Change
2024-12-31	$48.30B	7.32%
2023-12-31	$45.01B	-2.50%
2022-12-31	$46.16B	-0.49%
2021-12-31	$46.38B	9.09%
2020-12-31	$42.52B	62.62%
2019-12-31	$26.14B	15.89%
2018-12-31	$22.56B	8.59%
2017-12-31	$20.78B	6.94%
2016-12-31	$19.43B	17.31%
2015-12-31	$16.56B	4.29%
2014-12-31	$15.88B	-3.09%
2013-12-31	$16.39B	-7.01%
2012-12-31	$17.62B	-17.05%
2011-12-31	$21.24B	9.03%
2010-12-31	$19.48B	3.59%
2009-12-31	$18.81B	-8.69%
2008-12-31	$20.60B	6.46%
2007-12-31	$19.35B	8.00%
2006-12-31	$17.91B	-6.73%
2005-12-31	$19.21B	-0.89%
2004-12-31	$19.38B	-7.25%
2003-12-31	$20.89B	15.32%
2002-12-31	$18.12B	-6.71%
2001-12-31	$19.42B	6.63%
2000-12-31	$18.22B	-9.92%
1999-12-31	$20.22B	10.60%
1998-12-31	$18.28B	9.48%
1997-12-31	$16.70B	10.86%
1996-12-31	$15.06B	9.43%
1995-12-31	$13.77B	14.88%
1994-12-31	$11.98B	5.00%
1993-12-31	$11.41B	-

Bristol-Myers Squibb generated $48.30B in revenue during NA 2024, up 7.32% compared to the previous quarter, and up 184.74% compared to the same period a year ago.

Bristol-Myers Squibb Revenue by Quarter

Date	Revenue	Change
2025-09-30	$12.22B	-0.38%
2025-06-30	$12.27B	9.53%
2025-03-31	$11.20B	-9.24%
2024-12-31	$12.34B	3.78%
2024-09-30	$11.89B	-2.53%
2024-06-30	$12.20B	2.83%
2024-03-31	$11.87B	3.38%
2023-12-31	$11.48B	4.66%
2023-09-30	$10.97B	-2.32%
2023-06-30	$11.23B	-0.98%
2023-03-31	$11.34B	-0.60%
2022-12-31	$11.41B	1.68%
2022-09-30	$11.22B	-5.63%
2022-06-30	$11.89B	2.05%
2022-03-31	$11.65B	-2.81%
2021-12-31	$11.98B	3.11%
2021-09-30	$11.62B	-0.68%
2021-06-30	$11.70B	5.69%
2021-03-31	$11.07B	0.05%
2020-12-31	$11.07B	5.01%
2020-09-30	$10.54B	4.06%
2020-06-30	$10.13B	-6.05%
2020-03-31	$10.78B	35.70%
2019-12-31	$7.95B	32.26%
2019-09-30	$6.01B	-4.24%
2019-06-30	$6.27B	5.96%
2019-03-31	$5.92B	-0.89%
2018-12-31	$5.97B	4.96%
2018-09-30	$5.69B	-0.23%
2018-06-30	$5.70B	9.84%
2018-03-31	$5.19B	-4.70%
2017-12-31	$5.45B	3.71%
2017-09-30	$5.25B	2.14%
2017-06-30	$5.14B	4.36%
2017-03-31	$4.93B	-5.99%
2016-12-31	$5.24B	6.52%
2016-09-30	$4.92B	1.05%
2016-06-30	$4.87B	10.93%
2016-03-31	$4.39B	2.43%
2015-12-31	$4.29B	5.36%
2015-09-30	$4.07B	-2.26%
2015-06-30	$4.16B	3.02%
2015-03-31	$4.04B	-5.10%
2014-12-31	$4.26B	8.59%
2014-09-30	$3.92B	0.82%
2014-06-30	$3.89B	2.05%
2014-03-31	$3.81B	-14.19%
2013-12-31	$4.44B	9.25%
2013-09-30	$4.07B	0.42%
2013-06-30	$4.05B	5.66%
2013-03-31	$3.83B	-8.59%
2012-12-31	$4.19B	12.18%
2012-09-30	$3.74B	-15.91%
2012-06-30	$4.44B	-15.39%
2012-03-31	$5.25B	-3.72%
2011-12-31	$5.45B	2.04%
2011-09-30	$5.34B	-1.64%
2011-06-30	$5.43B	8.44%
2011-03-31	$5.01B	-1.96%
2010-12-31	$5.11B	6.52%
2010-09-30	$4.80B	0.63%
2010-06-30	$4.77B	-0.81%
2010-03-31	$4.81B	64.51%
2009-12-31	$2.92B	-46.75%
2009-09-30	$5.49B	1.91%
2009-06-30	$5.38B	7.36%
2009-03-31	$5.01B	-4.46%
2008-12-31	$5.25B	-0.10%
2008-09-30	$5.25B	0.98%
2008-06-30	$5.20B	0.42%
2008-03-31	$5.18B	5.86%
2007-12-31	$4.89B	-

Bristol-Myers Squibb generated $12.22B in revenue during Q3 2025, up -0.38% compared to the previous quarter, and up 100.17% compared to the same period a year ago.

Bristol-Myers Squibb Revenue Breakdown

Bristol-Myers Squibb Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
Opdualag	$928.00M	$252.00M	-	-	-
Orencia	$3.68B	$3.46B	$3.31B	$3.16B	$2.98B
Pomalyst/Imnovid	$3.54B	$3.50B	$3.33B	$3.07B	$322.00M
Reblozyl	$1.77B	$717.00M	$551.00M	$274.00M	-
Revlimid	$5.77B	$9.98B	$12.82B	$12.11B	$1.30B
Sotyktu	$246.00M	$8.00M	-	-	-
Sprycel	$1.29B	$2.17B	$2.12B	$2.14B	$2.11B
Yervoy	$2.53B	$2.13B	$2.03B	$1.68B	$1.49B
Zeposia	$566.00M	$250.00M	$134.00M	$12.00M	-
Abecma	$406.00M	$388.00M	$164.00M	-	-
Abraxane	$875.00M	$811.00M	$1.18B	$1.25B	$166.00M
Breyanzi	$747.00M	$182.00M	$87.00M	-	-
Augtyro	$38.00M	-	-	-	-
Camzyos	$602.00M	$24.00M	-	-	-
Eliquis	$13.33B	$11.79B	$10.76B	$9.17B	$7.93B
Opdivo	$9.30B	$8.25B	$7.52B	$6.99B	$7.20B
Mature Products And All Other	-	$1.75B	$1.90B	$1.31B	$1.67B
Onureg	-	$124.00M	$73.00M	$17.00M	-
Inrebic	-	$85.00M	$74.00M	$55.00M	$5.00M
Empliciti	-	$296.00M	$334.00M	$381.00M	$357.00M
Vidaza	-	-	-	$455.00M	$58.00M
Baraclude	-	-	-	$447.00M	$555.00M

Bristol-Myers Squibb's latest annual revenue breakdown by segment (product or service), as of Dec 24: Eliquis (29.22%), Opdivo (20.39%), Revlimid (12.65%), Orencia (8.07%), Pomalyst/Imnovid (7.77%), Yervoy (5.54%), Reblozyl (3.89%), Sprycel (2.82%), Opdualag (2.03%), Abraxane (1.92%), Breyanzi (1.64%), Camzyos (1.32%), Zeposia (1.24%), Abecma (0.89%), Sotyktu (0.54%), and Augtyro (0.08%).

Quarterly Revenue by Product

Product/Service	Sep 25	Jun 25	Mar 25	Sep 24	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Other Growth Brands	$514.00M	$470.00M	$403.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Abecma	$137.00M	$87.00M	$103.00M	$124.00M	$132.00M	$147.00M	$125.00M	$107.00M	$89.00M	$67.00M	$69.00M	$71.00M	$24.00M	-	-	-	-	-	-	-
Abraxane	$74.00M	$105.00M	$105.00M	$253.00M	$258.00M	$239.00M	$179.00M	$177.00M	$241.00M	$214.00M	$305.00M	$266.00M	$296.00M	$314.00M	$297.00M	$342.00M	$308.00M	$300.00M	-	-
Breyanzi	$359.00M	$344.00M	$263.00M	$224.00M	$100.00M	$71.00M	$55.00M	$44.00M	$39.00M	$44.00M	$40.00M	$30.00M	$17.00M	-	-	-	-	-	-	-
Camzyos	$296.00M	$260.00M	$159.00M	$156.00M	$46.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cobenfy	$43.00M	$35.00M	$27.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Eliquis	$3.75B	$3.68B	$3.56B	$3.00B	$3.20B	$3.42B	$2.69B	$2.65B	$3.23B	$3.21B	$2.67B	$2.41B	$2.79B	$2.89B	$2.27B	$2.10B	$2.16B	$2.64B	$2.03B	$1.93B
Krazati	$53.00M	$48.00M	$48.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Opdivo Ovantig	$67.00M	$30.00M	$9.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Opdivo	$2.53B	$2.56B	$2.27B	$2.36B	$2.15B	$2.20B	$2.22B	$2.05B	$2.06B	$1.92B	$1.99B	$1.91B	$1.91B	$1.72B	$1.79B	$1.78B	$1.65B	$1.77B	$1.76B	$1.82B
Opdualag	$299.00M	$284.00M	$252.00M	$233.00M	$154.00M	$117.00M	$104.00M	$84.00M	$58.00M	$6.00M	-	-	-	-	-	-	-	-	-	-
Orencia	$964.00M	$963.00M	$770.00M	$936.00M	$927.00M	$764.00M	$913.00M	$883.00M	$876.00M	$792.00M	$864.00M	$870.00M	$814.00M	$758.00M	$867.00M	$826.00M	$750.00M	$714.00M	$792.00M	$767.00M
Other Legacy Brands	$177.00M	$223.00M	$199.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pomalyst/Imnovid	$675.00M	$708.00M	$658.00M	$898.00M	$847.00M	$832.00M	$877.00M	$886.00M	$908.00M	$826.00M	$854.00M	$851.00M	$854.00M	$773.00M	$835.00M	$777.00M	$745.00M	$713.00M	-	-
Reblozyl	$615.00M	$568.00M	$478.00M	$447.00M	$234.00M	$206.00M	$199.00M	$190.00M	$172.00M	$156.00M	$151.00M	$160.00M	$128.00M	$112.00M	$115.00M	$96.00M	$55.00M	$8.00M	-	-
Revlimid	$575.00M	$838.00M	$936.00M	$1.41B	$1.47B	$1.75B	$2.26B	$2.42B	$2.50B	$2.80B	$3.33B	$3.35B	$3.20B	$2.94B	$3.28B	$3.03B	$2.88B	$2.92B	-	-
Sotyktu	$80.00M	$70.00M	$55.00M	$66.00M	$25.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sprycel	$119.00M	$120.00M	$175.00M	$290.00M	$458.00M	$429.00M	$578.00M	$560.00M	$544.00M	$483.00M	$555.00M	$551.00M	$541.00M	$470.00M	$564.00M	$544.00M	$511.00M	$521.00M	$549.00M	$558.00M
Yervoy	$739.00M	$728.00M	$624.00M	$642.00M	$585.00M	$508.00M	$568.00M	$523.00M	$525.00M	$515.00M	$545.00M	$515.00M	$510.00M	$456.00M	$471.00M	$446.00M	$369.00M	$396.00M	$385.00M	$353.00M
Zeposia	$161.00M	$150.00M	$107.00M	$147.00M	$100.00M	$78.00M	$79.00M	$69.00M	$66.00M	$36.00M	$48.00M	$40.00M	$28.00M	$18.00M	$9.00M	$2.00M	$1.00M	-	-	-
Augtyro	-	-	-	$10.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Mature and Other Brands	-	-	-	-	$472.00M	$467.00M	$441.00M	$435.00M	$462.00M	-	-	-	-	-	-	-	-	-	-	-
Inrebic	-	-	-	-	$27.00M	$25.00M	$23.00M	$21.00M	$23.00M	$18.00M	$20.00M	$22.00M	$16.00M	$16.00M	$15.00M	$13.00M	$15.00M	$12.00M	-	-
Onureg	-	-	-	-	$44.00M	$34.00M	$37.00M	$32.00M	$32.00M	$23.00M	$25.00M	$21.00M	$12.00M	$15.00M	$14.00M	$3.00M	-	-	-	-
Empliciti	-	-	-	-	-	-	$71.00M	$73.00M	$77.00M	$75.00M	$81.00M	$82.00M	$86.00M	$85.00M	$91.00M	$96.00M	$97.00M	$97.00M	$94.00M	$89.00M
Mature Products And All Other	-	-	-	-	-	-	-	-	-	-	$903.00M	$339.00M	$319.00M	$339.00M	$279.00M	$287.00M	$331.00M	$418.00M	$356.00M	$350.00M
Baraclude	-	-	-	-	-	-	-	-	-	-	-	$105.00M	$109.00M	$113.00M	$104.00M	$100.00M	$121.00M	$122.00M	$122.00M	$145.00M
Vidaza	-	-	-	-	-	-	-	-	-	-	-	$36.00M	$45.00M	$54.00M	$65.00M	$106.00M	$126.00M	$158.00M	-	-

Bristol-Myers Squibb's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Eliquis (30.64%), Opdivo (20.71%), Orencia (7.89%), Yervoy (6.04%), Pomalyst/Imnovid (5.52%), Reblozyl (5.03%), Revlimid (4.70%), Other Growth Brands (4.20%), Breyanzi (2.94%), Opdualag (2.45%), Camzyos (2.42%), Other Legacy Brands (1.45%), Zeposia (1.32%), Abecma (1.12%), Sprycel (0.97%), Sotyktu (0.65%), Abraxane (0.61%), Opdivo Ovantig (0.55%), Krazati (0.43%), and Cobenfy (0.35%).

Bristol-Myers Squibb Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 22	Dec 21	Dec 20	Dec 19
Other Region	$996.00M	$834.00M	$852.00M	$631.00M	$524.00M
UNITED STATES	$34.10B	$31.83B	$29.21B	$26.58B	$15.34B
Europe	-	$13.50B	-	-	-
European Union	-	$13.50B	$10.69B	$9.85B	$6.27B
Rest Of World	-	-	$5.63B	$5.46B	$4.01B

Bristol-Myers Squibb's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (97.16%), and Other Region (2.84%).

Quarterly Revenue by Country

Country	Sep 25	Jun 25	Mar 25	Sep 24	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
UNITED STATES	$8.33B	$8.52B	$7.87B	$8.23B	$7.89B	$8.03B	$7.92B	$7.94B	$8.27B	$7.69B	$7.52B	$7.30B	$7.39B	$7.01B	$6.78B	$6.54B	$6.49B	$6.77B	$4.75B	$3.47B
Other Region	$290.00M	$270.00M	$218.00M	$271.00M	$175.00M	$155.00M	$200.00M	$215.00M	$192.00M	$227.00M	$221.00M	$276.00M	$191.00M	$164.00M	$162.00M	$184.00M	$172.00M	$113.00M	$166.00M	$114.00M
Rest Of World	-	$3.48B	$3.11B	$3.39B	$3.16B	$1.31B	$1.46B	$1.39B	$1.44B	$1.35B	$1.43B	$1.36B	$1.33B	$1.33B	$1.18B	$976.00M	-	-	-	-
Europe	-	-	-	-	-	-	-	-	-	$2.41B	$2.66B	$2.69B	-	-	-	-	-	-	-	-
European Union	-	-	-	-	-	-	-	-	-	-	-	-	-	$2.55B	$2.70B	$2.45B	$2.14B	$2.57B	$1.85B	$1.45B

Bristol-Myers Squibb's latest quarterly revenue breakdown by geography, as of Sep 25: UNITED STATES (96.64%), and Other Region (3.36%).

Bristol-Myers Squibb Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
CVS	CVS Health	$372.81B	$102.87B
MCK	McKesson	$308.95B	$97.83B
CI	Cigna	$247.12B	$69.75B
ELV	Elevance Health	$176.81B	$50.71B
HCA	HCA Healthcare	$70.60B	$19.16B
PFE	Pfizer	$63.63B	$16.65B
BMY	Bristol-Myers Squibb	$48.30B	$12.22B
SNY	Sanofi	$43.07B	$11.12B
GSK	GSK	$30.33B	$7.36B
VRTX	Vertex Pharmaceuticals	$11.02B	$3.08B
ZTS	Zoetis	$9.26B	$2.40B

BMY Revenue FAQ

What is Bristol-Myers Squibb’s yearly revenue?

Bristol-Myers Squibb's yearly revenue for 2024 was $48.3B, representing an increase of 7.32% compared to 2023. The company's yearly revenue for 2023 was $45.01B, representing a decrease of -2.50% compared to 2022. BMY's yearly revenue for 2022 was $46.16B, representing a decrease of -0.49% compared to 2021.

What is Bristol-Myers Squibb’s quarterly revenue?

Bristol-Myers Squibb's quarterly revenue for Q3 2025 was $12.22B, a -0.38% decrease from the previous quarter (Q2 2025), and a 2.77% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $12.27B, a 9.53% increase from the previous quarter (Q1 2025), and a 0.56% increase year-over-year (Q2 2024). BMY's quarterly revenue for Q1 2025 was $11.2B, a -9.24% decrease from the previous quarter (Q4 2024), and a -5.60% decrease year-over-year (Q1 2024).

What is Bristol-Myers Squibb’s revenue growth rate?

Bristol-Myers Squibb's revenue growth rate for the last 3 years (2022-2024) was 4.64%, and for the last 5 years (2020-2024) was 13.60%.

What are Bristol-Myers Squibb’s revenue streams?

Bristol-Myers Squibb's revenue streams in c 24 are Opdualag, Orencia, Pomalyst/Imnovid, Reblozyl, Revlimid, Sotyktu, Sprycel, Yervoy, Zeposia, Abecma, Abraxane, Breyanzi, Augtyro, Camzyos, Eliquis, and Opdivo. Opdualag generated $928M in revenue, accounting 2.03% of the company's total revenue, up 268.25% year-over-year. Orencia generated $3.68B in revenue, accounting 8.07% of the company's total revenue, up 6.29% year-over-year. Pomalyst/Imnovid generated $3.54B in revenue, accounting 7.77% of the company's total revenue, up 1.37% year-over-year. Reblozyl generated $1.77B in revenue, accounting 3.89% of the company's total revenue, up 147.28% year-over-year. Revlimid generated $5.77B in revenue, accounting 12.65% of the company's total revenue, down -42.14% year-over-year. Sotyktu generated $246M in revenue, accounting 0.54% of the company's total revenue, up 2975.00% year-over-year. Sprycel generated $1.29B in revenue, accounting 2.82% of the company's total revenue, down -40.60% year-over-year. Yervoy generated $2.53B in revenue, accounting 5.54% of the company's total revenue, up 18.72% year-over-year. Zeposia generated $566M in revenue, accounting 1.24% of the company's total revenue, up 126.40% year-over-year. Abecma generated $406M in revenue, accounting 0.89% of the company's total revenue, up 4.64% year-over-year. Abraxane generated $875M in revenue, accounting 1.92% of the company's total revenue, up 7.89% year-over-year. Breyanzi generated $747M in revenue, accounting 1.64% of the company's total revenue, up 310.44% year-over-year. Augtyro generated $38M in revenue, accounting 0.08% of the company's total revenue Camzyos generated $602M in revenue, accounting 1.32% of the company's total revenue, up 2408.33% year-over-year. Eliquis generated $13.33B in revenue, accounting 29.22% of the company's total revenue, up 13.10% year-over-year. Opdivo generated $9.3B in revenue, accounting 20.39% of the company's total revenue, up 12.79% year-over-year.

What is Bristol-Myers Squibb’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Bristol-Myers Squibb was Eliquis. This segment made a revenue of $13.33B, representing 29.22% of the company's total revenue.